BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Dorsey & Whitney Trust CO LLC 32,975$11,430,0001.16%
ROWLANDMILLER & PARTNERS.ADV 13,070$4,530,584,0001.16%
Ascension Asset Management LLC 4,463$1,547,0001.14%
Champlain Investment Partners, LLC 493,595$171,100,0001.11%
Values First Advisors, Inc. 4,387$1,521,0001.08%
ARGUS INVESTORS' COUNSEL, INC. 4,142$1,436,0001.06%
RIVERBRIDGE PARTNERS LLC 404,924$140,363,0001.06%
Stephens Investment Management Group LLC 163,270$56,596,0001.05%
Fluent Financial, LLC 5,691$1,973,0001.01%
Sanchez Wealth Management Group 5,639$1,955,0000.97%
Legal Advantage Investments, Inc. 2,700$936,0000.91%
SEGALL BRYANT & HAMILL, LLC 217,241$75,280,0000.85%
ROBERTS GLORE & CO INC /IL/ 7,106$2,463,0000.82%
FRED ALGER MANAGEMENT, LLC 501,778$173,936,0000.81%
SANDLER CAPITAL MANAGEMENT 20,690$7,172,0000.76%
Artemis Investment Management LLP 198,993$69,128,0000.71%
ATLANTA CAPITAL MANAGEMENT CO L L C 472,726$163,866,0000.71%
Covea Finance 14,500$5,026,0000.70%
Kensington Investment Counsel, LLC 2,326$806,0000.69%
Berger Financial Group, Inc 12,536$4,345,0000.64%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.